Limits...
Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms.

Lee D, Wilson K, Akehurst R, Cowie MR, Zannad F, Krum H, van Veldhuisen DJ, Vincent J, Pitt B, McMurray JJ, Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) Stu - Heart (2014)

Bottom Line: The present study evaluated the cost-effectiveness of eplerenone in the treatment of these patients in the UK and Spain.Probabilistic sensitivity analysis suggested a 100% likelihood of eplerenone being regarded as cost-effective at a willingness-to-pay threshold of £20 000 per QALY (UK) or €30 000 per QALY (Spain).By currently accepted standards of value for money, the addition of eplerenone to optimal medical therapy for patients with chronic systolic HF and mild symptoms is likely to be cost-effective.

View Article: PubMed Central - PubMed

Affiliation: BresMed, Sheffield, UK.

Show MeSH

Related in: MedlinePlus

Incremental quality-adjusted life expectancy and lifetime costs. QALY, quality-adjusted life year; WTP, willingness-to-pay threshold.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4215293&req=5

HEARTJNL2014305673F3: Incremental quality-adjusted life expectancy and lifetime costs. QALY, quality-adjusted life year; WTP, willingness-to-pay threshold.

Mentions: A probabilistic sensitivity analysis (PSA) was also performed, producing 100 pairs of incremental effectiveness and cost results. These were plotted on a cost-effectiveness plane to illustrate the probability of being cost-effective for both countries’ willingness-to-pay (WTP) thresholds (figure 3).


Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms.

Lee D, Wilson K, Akehurst R, Cowie MR, Zannad F, Krum H, van Veldhuisen DJ, Vincent J, Pitt B, McMurray JJ, Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) Stu - Heart (2014)

Incremental quality-adjusted life expectancy and lifetime costs. QALY, quality-adjusted life year; WTP, willingness-to-pay threshold.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4215293&req=5

HEARTJNL2014305673F3: Incremental quality-adjusted life expectancy and lifetime costs. QALY, quality-adjusted life year; WTP, willingness-to-pay threshold.
Mentions: A probabilistic sensitivity analysis (PSA) was also performed, producing 100 pairs of incremental effectiveness and cost results. These were plotted on a cost-effectiveness plane to illustrate the probability of being cost-effective for both countries’ willingness-to-pay (WTP) thresholds (figure 3).

Bottom Line: The present study evaluated the cost-effectiveness of eplerenone in the treatment of these patients in the UK and Spain.Probabilistic sensitivity analysis suggested a 100% likelihood of eplerenone being regarded as cost-effective at a willingness-to-pay threshold of £20 000 per QALY (UK) or €30 000 per QALY (Spain).By currently accepted standards of value for money, the addition of eplerenone to optimal medical therapy for patients with chronic systolic HF and mild symptoms is likely to be cost-effective.

View Article: PubMed Central - PubMed

Affiliation: BresMed, Sheffield, UK.

Show MeSH
Related in: MedlinePlus